In different preclinical, diet-induced MASH mouse models, several groups have shown that the application of NLRP3 inhibitors (MCC950 or IFM-514) suppressed the severity of hepatic inflammation and fibrosis (Mridha et al., 2017; Torres et al., 2021). The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.